Race Oncology Expands RC220 Clinical Trial to Second Site

Race Oncology Ltd. ( (AU:RAC) ) has shared an announcement.

Race Oncology Ltd has announced the activation of a second site for its Phase 1 clinical trial of RC220, in combination with doxorubicin, targeting advanced solid tumors at the Central Coast Local Health District in Australia. This expansion is expected to accelerate patient recruitment and data collection on safety, tolerability, and pharmacokinetics, potentially enhancing Race’s position in the oncology market by providing insights into the cardioprotective and anticancer efficacy of RC220.

More about Race Oncology Ltd.

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company focused on cancer care. Its lead asset, bisantrene, is an anticancer drug known for its therapeutic benefits and reduced cardiotoxicity compared to anthracyclines like doxorubicin. The company is advancing a reformulated version, RC220, to address unmet oncology needs and is exploring its effects on the m6A RNA pathway.

YTD Price Performance: -31.48%

Average Trading Volume: 108,403

Technical Sentiment Signal: Buy

Current Market Cap: A$160.7M

Find detailed analytics on RAC stock on TipRanks’ Stock Analysis page.